EMA advises patients on GLP-1 receptor agonist weight-loss drugs to inform doctors before general anesthesia due to respiratory risks.

The European Medicines Agency (EMA) has advised patients taking weight-loss drugs, such as Wegovy and Zepbound, to inform their doctors prior to general anesthesia or deep sedation surgery due to potential respiratory complications linked to these medications. These weight-loss drugs belong to a class called GLP-1 receptor agonists, which slow gastric emptying and make users feel full for longer periods.